Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Alternative efficacy-predicting markers for paclitaxel instead of CHFR in non-small-cell lung cancer.

Cancer biology & therapy - 1 Nov 2010

Takeshita Masafumi, Koga Takaomi, Takayama Koichi, Yano Tokujiro, Maehara Yoshihiko, Nakanishi Yoichi, Sueishi Katsuo

Abstract excerpt

Experiments using cancer cell lines have revealed that CHFR methylation correlates with sensitivity to microtubule inhibitors. However, this marker may not benefit actual clinical cases because it is difficult to detect CHFR methylation without surgically resected samples. Thus, a more easily accessible marker that correlates with sensitivity to microtubule inhibitors might be useful in NSCLC, especially in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Phytogenic
Share to Genes, erbB-1

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neoplasm Proteins

Share to Paclitaxel

Share to Poly-ADP-Ribose Binding Proteins

Share to Smoking

Share to Succinate Dehydrogenase

Share to Ubiquitin-Protein Ligases

Source

Identifiers

PMID: 20855974
DOI: 10.4161/cbt.10.9.13320

Genes

CHFR
EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

Alternative efficacy-predicting markers for paclitaxel instead of CHFR in non-small-cell lung cancer.PMID 20855974Read ↗

Associations between driver gene mutations and cytotoxic chemosensitivity in patients with non-small cell lung cancer.Semantic proximity Read ↗

First-line therapy and methylation status of CHFR in serum influence outcome to chemotherapy versus EGFR tyrosine kinase inhibitors as second-line therapy in stage IV non-small-cell lung cancer patients.Semantic proximity Read ↗

Molecular characteristics of non-small cell lung cancer with reduced CHFR expression in The Cancer Genome Atlas (TCGA) project.Semantic proximity Read ↗

NSCLC as the Paradigm of Precision Medicine at Its Finest: The Rise of New Druggable Molecular Targets for Advanced Disease.Semantic proximity Read ↗

Prognostic Factors and Markers in Non-Small Cell Lung Cancer: Recent Progress and Future Challenges.Semantic proximity Read ↗

Genetic Alterations in NSCLC: Prognostic Implications and Impact on Therapeutic Resistance.Semantic proximity Read ↗

FOXM1 targeting alters AURKB activity and reshapes antitumor immunity to curb the progression of small cell lung cancerSemantic proximity Read ↗

Histo-Molecular Factors of Response to Combined Chemotherapy and Immunotherapy in Non-Small Cell Lung Cancers.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.